Low dose inhaled glucocorticoid is superior to anti-leukotrienes
Using leukotriene receptor antagonists instead of inhaled
glucocorticoids to treat patients with mild to moderate asthma
increases the risk of an exacerbation. In a systematic review of 13 trials comparing the treatments, Ducharme (p 621) determined that the risk of exacerbations of asthma requiring systemic glucocorticoids was
60% higher with anti-leukotrienes than inhaled glucocorticoids. Until
further evidence is available on the safety and efficacy of
anti-leukotrienes as single agent therapy, inhaled glucocorticoids should remain the standard treatment for asthma.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Relevant Article
- Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence
- Francine M Ducharme
BMJ 2003 326: 621.[Abstract] [Full Text] [PDF]
This article
- Respond to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
Services
- Email this article to a friend
- Find similar articles in BMJ
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
Related content
Bookmark with
What's new
Latest blogs
Services
Tools
Online poll
Resources
Rapid responses for this article
There are no rapid responses for this article.Most read last week
Print issues
